Your browser doesn't support javascript.
loading
Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases.
Sini, Patrizia; Gürtler, Ulrich; Zahn, Stephan K; Baumann, Christoph; Rudolph, Dorothea; Baumgartinger, Rosa; Strauss, Eva; Haslinger, Christian; Tontsch-Grunt, Ulrike; Waizenegger, Irene C; Solca, Flavio; Bader, Gerd; Zoephel, Andreas; Treu, Matthias; Reiser, Ulrich; Garin-Chesa, Pilar; Boehmelt, Guido; Kraut, Norbert; Quant, Jens; Adolf, Günther R.
Afiliação
  • Sini P; Department of Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria. patrizia.sini@boehringer-ingelheim.com.
  • Gürtler U; Department of R&D Project Management, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
  • Zahn SK; Department of Medicinal Chemistry, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Baumann C; Department of Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Rudolph D; Department of Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Baumgartinger R; Department of Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Strauss E; Department of Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Haslinger C; Department of Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Tontsch-Grunt U; Department of Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Waizenegger IC; Department of Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Solca F; Department of Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Bader G; Department of Medicinal Chemistry, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Zoephel A; Department of Medicinal Chemistry, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Treu M; Department of Medicinal Chemistry, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Reiser U; Department of Medicinal Chemistry, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Garin-Chesa P; Department of Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Boehmelt G; Research Networking, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Kraut N; Department of Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Quant J; Research ADME, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Adolf GR; Department of Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Mol Cancer Ther ; 15(10): 2388-2398, 2016 10.
Article em En | MEDLINE | ID: mdl-27496137
Assuntos
Buscar no Google
Imprimir
XML
PubMed Links

Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quinases de Proteína Quinase Ativadas por Mitógeno / Inibidores de Proteínas Quinases / Aurora Quinases / Antineoplásicos Limite: Animals / Female / Humans Idioma: En Revista: Mol Cancer Ther Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Áustria
Buscar no Google
Imprimir
XML
PubMed Links

Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quinases de Proteína Quinase Ativadas por Mitógeno / Inibidores de Proteínas Quinases / Aurora Quinases / Antineoplásicos Limite: Animals / Female / Humans Idioma: En Revista: Mol Cancer Ther Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Áustria